Log in
OTCMKTS:GNMSF

Genmab A/S Stock Forecast, Price & News

$336.36
-9.85 (-2.85 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$330.90
Now: $336.36
$339.06
50-Day Range
$340.86
MA: $366.24
$389.00
52-Week Range
$159.45
Now: $336.36
$391.76
Volume150 shs
Average Volume2,447 shs
Market Capitalization$20.75 billion
P/E Ratio4.78
Dividend YieldN/A
Beta0.65
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Read More
Genmab A/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNMSF
CUSIPN/A
CIKN/A
Phone45-7020-2728
Employees636

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$804.57 million
Cash Flow$5.19 per share
Book Value$34.13 per share

Profitability

Net Income$324.68 million

Miscellaneous

Market Cap$20.75 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$336.36
-9.85 (-2.85 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNMSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Genmab A/S (OTCMKTS:GNMSF) Frequently Asked Questions

How has Genmab A/S's stock been impacted by Coronavirus?

Genmab A/S's stock was trading at $211.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GNMSF shares have increased by 59.4% and is now trading at $336.36.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Genmab A/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Genmab A/S
.

When is Genmab A/S's next earnings date?

Genmab A/S is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Genmab A/S
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) posted its quarterly earnings data on Wednesday, August, 12th. The company reported $65.11 earnings per share (EPS) for the quarter. The company had revenue of $805.11 million for the quarter. Genmab A/S had a net margin of 54.67% and a return on equity of 38.31%.
View Genmab A/S's earnings history
.

Are investors shorting Genmab A/S?

Genmab A/S saw a drop in short interest in October. As of October 15th, there was short interest totaling 11,500 shares, a drop of 35.0% from the September 30th total of 17,700 shares. Based on an average daily trading volume, of 300 shares, the days-to-cover ratio is presently 38.3 days.
View Genmab A/S's Short Interest
.

Who are some of Genmab A/S's key competitors?

Who are Genmab A/S's key executives?

Genmab A/S's management team includes the following people:
  • Dr. Jan G. J. van de Winkel, Co-Founder, Pres & CEO (Age 59)
  • Mr. Peter Storm Kristensen, Associate Director of Legal & Non-Independent Director (Age 45)
  • Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 62)
  • Dr. Mijke Zachariasse Ph.D., Director of Protein Production & Chemistry and Non-Independent Director (Age 46)
  • Mr. Daniel J. Bruno, VP, Corp. Controller & Non-Independent Director (Age 40)

What is Genmab A/S's stock symbol?

Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."

How do I buy shares of Genmab A/S?

Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genmab A/S's stock price today?

One share of GNMSF stock can currently be purchased for approximately $336.36.

How big of a company is Genmab A/S?

Genmab A/S has a market capitalization of $20.75 billion and generates $804.57 million in revenue each year. Genmab A/S employs 636 workers across the globe.

What is Genmab A/S's official website?

The official website for Genmab A/S is www.genmab.com.

How can I contact Genmab A/S?

Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.